Pierre-Dominique G.
- Country
- Belgium
- Department
- Dermatology Department
Research Overview
- Phase 3 Extension Study of Long-Term Safety and Efficacy of Remibrutinib in Adults With Moderate to Severe Hidradenitis Suppurativa
- Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Enpatoran for Active Cutaneous Lupus Erythematosus (with or without systemic disease)
- Efficacy and Safety of Guselkumab Versus Etanercept in Pediatric Chronic Plaque Psoriasis: A Randomized, Placebo-Controlled Phase 3 Trial
Data & Insights
Has run more than one trial at 447 of 722 partner sites.
Specializations
Inflammatory Skin Conditions
Specialized in treating hidradenitis suppurativa, conducting research with various therapeutic agents including sonelokimab, spesolimab, lutikizumab, and povorcitinib. Also investigates pyoderma gangrenosum treatment approaches.
- Chronic inflammatory disorders
- Novel therapeutic compounds
- Treatment-resistant cases
Psoriasis Research
Focuses on moderate to severe plaque psoriasis and generalized pustular psoriasis. Conducts studies on biological therapies including guselkumab and innovative treatment monitoring approaches.
- Adult and pediatric populations
- Biological therapeutics
- Treatment optimization
Advanced Dermatology
Investigates treatments for atopic dermatitis, alopecia areata, and vitiligo. Studies innovative applications of upadacitinib and ruxolitinib across multiple dermatological conditions.
- Autoimmune skin disorders
- Systemic treatments
- Long-term therapeutic outcomes
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.